Dana Levasseur, Ph.D. Vice President, Hematology
Dr. Dana Levasseur is the Vice President for Hematology at Beam Therapeutics. He has more than 20 years of experience developing genetic delivery systems and therapies, spanning roles through early discovery to clinical entry.
Prior to joining Beam Therapeutics, Dr. Levasseur led research efforts at Bioverativ, where he was responsible for moving the first gene edited therapy for sickle cell disease (BIVV003), and the first gene editing therapeutic in the U.S. for beta thalassemia (ST-400), through FDA IND approval. Previously, at Novartis Institutes for BioMedical Research, Dr. Levasseur led a preclinical team responsible for integrated lead discovery of small molecules for neurologic, cardiometabolic and liver disease programs, and for expanding more clinically relevant cell modeling and screening approaches across Novartis disease programs. Before joining Novartis, he ran a research program centered on hematopoietic and pluripotent stem cell gene delivery and regulation at the University of Iowa, where he was a March of Dimes Basil O’Connor Scholar.
Dr. Levasseur received a Ph.D. in Molecular Genetics and Biochemistry from the University of Alabama, followed by postdoctoral studies at Harvard Medical School.